SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.
For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov
SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.
For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov
Indication
Therapeutic Candidate
Meniere’s Disease
SPI-1005
(Phase 2)
For more information regarding ongoing or upcoming studies see Clinicaltrials.gov
Acute NIHL
Mild to Moderate
SPI-1005
(Phase 2)
published in The Lancet – July 2017
For more information regarding ongoing or upcoming studies see Clinicaltrials.gov
Aminoglycoside-Induced Ototoxicity
SPI-3005
(Phase 1)
see presentation at 2018 NACFC
A phase 2 study to test the safety and tolerability of SPI-1005 in people with cystic fibrosis is currently underway. Details here.
For more information regarding ongoing or upcoming studies see Clinicaltrials.gov
COVID-19
SPI-1005
(Phase 1)
Chemotherapy-Induced Ototoxicity
SPI-3005
(Phase 1)
Severe to Profoundly
Impaired
SPI-5557
(Phase 1)